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CC BY-NC-ND license (http://creativeZika virus was initially discovered in east Africa about 70 years ago and remained a neglected
arboviral disease in Africa and Southeast Asia. The virus first came into the limelight in 2007
when it caused an outbreak in Micronesia. In the ensuing decade, it spread widely in other Pa-
cific islands, after which its incursion into Brazil in 2015 led to a widespread epidemic in Latin
America. In most infected patients the disease is relatively benign. Serious complications
include GuillaineBarre´ syndrome and congenital infection which may lead to microcephaly
and maculopathy. Aedes mosquitoes are the main vectors, in particular, Ae. aegypti. Ae. albo-
pictus is another potential vector. Since the competent mosquito vectors are highly prevalent
in most tropical and subtropical countries, introduction of the virus to these areas could
readily result in endemic transmission of the disease. The priorities of control include reinfor-
cing education of travellers to and residents of endemic areas, preventing further local trans-
mission by vectors, and an integrated vector management programme. The container habitats
of Ae. aegypti and Ae. albopictus means engagement of the community and citizens is of
utmost importance to the success of vector control.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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The past decades have seen some hitherto exotic arbovi-
ruses and other arthropod-borne infections emerging from
oblivion into epidemic diseases of global concern. The
burden of dengue has been rising for five decades.1 The
2004e2005 outbreak of chikungunya in East Africa and In-
dian Ocean was followed by worldwide spread in both the
Old and New Worlds in the ensuing decade.2 The expanding
geographical distribution of these arboviral diseases is
further fuelled by climate changes and importation of
invasive arthropod species (most notably various Aedes
mosquitoes such as Ae. albopictus, Ae. japonicus, Ae.
aegypti, and Ae. koreicus) into temperate countries of
Europe and North America.3,4 The consequences of climate
change and vector distribution can be seen in the autoch-
thonous transmission of dengue and chikungunya in high-
latitude areas such as Japan and European countries.5,6,
Zika virus is the latest culprit in a long list of arbovirus
epidemics that emerged in the past two decades. As a
largely neglected disease, little is known about the basic
biology of the virus and the disease until the past decade
when it made its mark outside Africa, not to mention vac-
cine development and antiviral studies. At the time of
writing (early 2016), the epidemic in Latin America is still
evolving. As in the case of other emerging epidemics such
as chikungunya, new clinical and laboratory features may
be recognized which may impact on future management of
the disease. We herewith summarized what is currently
known about the infection, highlighted the uncertainties,
and examined the approaches to prevention and control of
similar arthropod-borne infections which are pertinent to
areas with risks of disease introduction and transmission.Virology
The family Flaviviridae contains some of the most clinically
important arboviruses (Table 1). The prototype agent,
yellow fever virus, is indeed the first human virus discov-
ered and found to be transmitted by an arthropod vector.7,8
There are currently four genera in Flaviviridae, Flavivirus
(53 species), Hepacivirus (one species, the hepatitis C
virus), Pegivirus (two species), and Pestivirus (four spe-
cies).9 With the exception of the hepatitis C virus, most ofTable 1 Key clinical and epidemiological features of important
Main clinical syndromea
Mosquito-borne
Central nervous system
infection
Japanese encephalitis viru
encephalitis virus, Ntaya
St. Louis encephalitis viru
West Nile virus
Viscerotropic
infections  haemorrhagic
fever
Yellow fever virus, dengue
Febrile illnesses Dengue virus, Ilheus virus
Spondweni virus, Zika viru
a Overlaps in the clinical syndromes do occur for individual viruses.the clinically relevant pathogens belong to the genus Fla-
vivirus. Epidemiologically, the arthropod-borne flaviviruses
can be divided into mosquito-borne and tick-borne viruses.
Flaviviruses with no known vectors are also found in ani-
mals. Clinically, the most prominent syndromes caused by
flaviviruses are undifferentiated febrile illnesses (often
presenting as a fever with rash syndrome), central nervous
system infection (especially encephalitis), visceral
involvement, and haemorrhagic fever.
Flaviviruses are enveloped, single-stranded, positive
sense RNA viruses measuring about 50 nm in size. The viral
genome is about 10.5 to 11 kbp in size.12,13 The viral
genome produces a polyprotein with more than 3000 amino
acids; this polyproptein is then cleaved into three struc-
tural and seven non-structural proteins.10 The flaviviral
genome encodes (from 50 to 30 end, i.e. from N- to C-ter-
minal of the polyprotein) the structural C (capsid,
w11 kDa), prM (precursor M protein, w26 kDa, which is
further cleaved into the M protein), and E (envelope,
w53 kDa) proteins, and the non-structural NS1 (w46 kDa),
NS2A (w22 kDa), NS2B (w14 kDa), NS3 (w70 kDa), NS4A
(w16 kDa), NS4B (w27 kDa), and NS5 (w103 kDa) pro-
teins.10 Structurally, the E and M proteins are
located at the surface of the viral particles, while the
nucleocapsid is made up of the C protein and the genomic
RNA molecule.
Table 2 summarizes the key functions and host effects of
the flaviviral proteins. It must be remembered that the
current knowledge on the effects of various viral proteins
on host immune system and pathogenesis is based on pre-
vious studies on clinically important flaviviruses such as
dengue virus, West Nile virus, yellow fever virus, Japanese
encephalitis virus, and tick-borne encephalitis virus.
Whether the findings can be generalized to other flavivi-
ruses including Zika virus is unknown.
Initial isolation of Zika virus was made from a sentinel
rhesus monkey in 1947 in the Zika Forest area of the
Entebbe Peninsula in Uganda on the northwestern shore of
Lake Victoria.28 In 1948, the virus was also detected in a
batch of Aedes africanus mosquitoes.28 Isolation of the
virus from humans were then reported in Uganda, Tanzania,
and Nigeria in the 1950s.29,30 The genomes of the three
human isolates of Zika virus are 10,676 bp in size, which is
comparable to other members of Flaviviridae.31 Zika virus
is phylogenetically closest to the Spondweni virus, which isflaviviruses causing human infections.10,11
Vectors
Tick-borne
s, Murray Valley
virus, Rocio virus,
s, Usutu virus,
Louping ill virus, Powassan virus,
tick-borne encephalitis virus
virus Alkhumra virus, Kyasanur Forest
disease virus, Omsk haemorrhagic
fever virus
, Kokobera virus,
s
Table 2 Key proteins of flaviviruses and their functions.10,14e27
Proteins Functions Possible effects on hosts
C RNA binding to form the nucleocapsid.
prM, M Stabilization, assisting the folding and secretion of
E protein.
Antibodies towards prM enhances infectivity of immature
virions, could be involved in pathogenesis of severe
dengue in secondary infections.
E Receptor binding, membrane fusion.
NS1 RNA replication. Localization to host cell surface and secreted extracellularly;
modulates signalling of innate immune system, possible
damages to platelets and endothelial cells through anti-NS1
antibodies, antagonizes C4 complement.
NS2A RNA synthesis and viral assembly. Interferon antagonist, induces host cell apoptosis.
NS2B Complexes with NS3 to function as serine protease.
NS3 Complexes with NS2B to function as serine protease;
possess RNA helicase and triphosphatasae activities.
Induces apoptosis of host cells, modulates host microRNA,
one of the targets of cytotoxic T cell response.
NS4A RNA replication. Blocks type I interferon signalling, induces autophagy and
protects host cells from death during infection.
NS4B RNA replication. Blocks type I interferon signalling and RNA interference,
modulator of stress granules in host cells.
NS5 Methytransferase and RNA guanylyltransferase
activities; capping and synthesis of RNA;
RNA-dependent RNA polymerase.
Blocks type I interferon signalling.
228 S.S.-Y. Wong et al.also a mosquito-borne flavivirus that has been found to
cause a febrile illness in Africa.32
Several flaviviruses are noted for their propensity to
cause central nervous system infections, in particular, en-
cephalitis (Table 1). Globally, Japanese encephalitis virus,
Murray Valley encephalitis virus, St. Louis encephalitis
virus, West Nile virus, and tick-borne encephalitis (and to
some extent, dengue virus, though neurological involve-
ment is generally not a common feature of dengue) are the
most commonly encountered pathogens in this regard.33 In
addition to the wild-type viruses, even apparently attenu-
ated vaccine strains may still possess some degree of neu-
rovirulence, as demonstrated by the yellow fever 17D
vaccine.34 The exact genetic determinants of flaviviral
neurovirulence have not been completely elucidated,
though it appears to be related to multiple genes such as E,
NS1, NS3, and NS5.33,35e41 This area is particularly relevant
to Zika virus infection which was previously considered to
be a relatively harmless febrile illness with low case-
fatality ratio, but microcephaly has emerged as a unique
potential sequel of the infection in pregnant women during
the Latin American epidemic that began in 2015. Although
the exact causality, risk, and mechanism between the
infection and microcephaly remain to be investigated, a
recent report described the presence of Zika virus in the
brain tissues of an affected foetus as demonstrated by both
reverse transcription polymerase chain reaction (RT-PCR)
and electron microscopy.42
The phylogenetic relationships of flaviviruses have been
well studied.12,13,43 Phylogeny is most commonly studied by
NS5 sequences, but the NS3 and E sequences or the entire
coding region have also been utilized for studies. In gen-
eral, clustering of flaviviruses can be seen in phylogenetic
trees based on the type of transmission vectors (mosquitoes
[Aedes versus Culex], ticks, or no known vectors), type of
clinical syndromes (encephalitic versus non-encephaliticdiseases), and geographical distribution of the viruses.12
Figure 1 shows the phylogenetic relationship of the clini-
cally relevant flaviviruses found in humans. As expected,
phylogenetic trees based on NS5 and E sequences showed a
clear clustering of the mosquito-borne versus tick-borne
viruses, and viruses that cause central nervous system in-
fections are also clustered together. Although Zika virus
does possess neuropathogenic potentials, at least in the
immature nervous system, it is not particularly closely
related to other encephalitic viruses. It might be noted that
the other potential serious complication of Zika virus
infection, Guillain-Barre´ syndrome (vide infra), also affects
the nervous system, albeit probably via a different patho-
genic mechanism. Moreover, in infants with congenital
infection, abnormalities of the retina (which is essentially a
part of the central nervous system) were also detected
(vide infra). Whether the phylogeny explains why Zika virus
is not highly neurovirulent in adults but causes substantial
damage to the immature neural tissues and possibly induces
immunopathological damage in the adult nervous system
remains to be studied. Another question begging for an
answer is whether both lineages of Zika virus are equally
neurovirulent for the foetal brain. This is relevant because
the Yap 2007 strain and the Senegal 1984 strain of Zika virus
differ from the prototype Uganda strain in that the latter
has a four amino acid deletion in the E protein.44 Micro-
cephaly has not been reported previously in Africa where
the disease is endemic (although the possibility of under-
reporting cannot be excluded). Whether the difference in
the four amino acids or other genetic changes is associated
with virulence or transmissibility is currently unknown.
Figure 1 also shows a clear separation of Zika viruses into
the African and Asian lineages.45 It has been suggested that
Zika virus originated in east Africa near Uganda, which
subsequently spread to west Africa and central Africa (the
African lineage).46 The Uganda strain also spread to
Figure 1 Phylogenetic trees showing the relationships between important flaviviruses causing human infection. A total of 1,536
nucleotide positions in envelope (E ) gene (Figure 1A), 1,067 nucleotide positions in non-structural protein 1 (NS1) (Figure 1B), 1,925
nucleotide positions in non-structural protein 3 (NS3) (Figure 1C), 2,736 nucleotide positions in non-structural protein 5 (NS5) genes
(Figure 1D) were included in the analysis. The trees were constructed using the neighbour-joining method. The bootstrap values
calculated from1,000 trees are shownwhen they are70%. The scale bar indicates the estimated number of substitutions per 20 bases
in E andNS3 and per 50 bases inNS1 andNS5. The names and accession numbers (in parentheses) are presented as cited in theGenBank
database. * Mosquito-borne neurotropic viruses; y tick-borne neurotropic viruses; z tick-borne haemorrhagic fever viruses.
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Table 3 Outbreaks of human Zika virus infection since 2007.59e63
Year Location Estimated number of cases Notable features
2007 Yap Island,
Micronesia
49 confirmed, 59 probable, and 72 suspected
cases in one study. Estimated over 900 clinical
cases, 73% of population infected in 4 months.
Aedes hensilli implicated as the main vector.
2007 Gabon Detected in 5 archived human samples; total
number of cases unknown.
Retrospective study of a concurrent outbreak
of dengue and chikungunya; detection of virus
in patient sera and Ae. albopictus pools.
2013e2014 French
Polynesia
8,723 suspected cases, over 30,000 sought
medical care.
Derived from the Asian lineage, closely related
to Cambodia 2010 and Yap state 2007 strains.
Association with Guillain-Barre´ syndrome and
other neurological complications suspected.
2014 The Cook Islands 932 suspected, 50 confirmed cases.
2014 New Caledonia 1400 confirmed cases (35 imported).
2014 Easter Island 51 confirmed out of 89 suspected cases from
Jan e May 2014.
Infecting strain closely related to viral strain
found in French Polynesia.
2015 Latin Americaa Estimated 1.5 million cases in Brazil. Association with microcephaly and maculopathy
suspected.
a As of 10 February 2016. Includes Barbados, Bolivia, Colombia, Commonwealth of Puerto Rico, Costa Rica, Curacao, Dominican
Republic, Ecuador, El Salvador, French Guiana, Guadeloupe, Guatemala, Guyana, Haiti, Honduras, Jamaica, Martinique, Mexico,
Nicaragua, Panama, Paraguay, Saint Martin, Suriname, U.S. Virgin Islands, Venezuela.
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lineage. The Yap outbreak in 2007, French Polynesian
outbreak in 2013e2014, and the Latin American epidemic
since 2015 were due to viruses belonging to the Asian
lineage, probably originating from a strain from Southeast
Asia.44,45,47
The pathogenesis of Zika virus infection in humans is
poorly understood, though studies are starting to unravel
the disease process. In a study on the effects of Zika virus,
human skin cells, the fibroblasts, keratinocytes, and den-
dritic cells are all permissive to infection with replication of
the virus.48 Molecules such as DC-SIGN, AXL, Tyro3, and
TIM-1 are involved in cell entry, and both type I and type II
interferons inhibit viral multiplication. The utilization of
multiple cellular receptors for entry is similar to dengue
virus. Another study described the cytokine profiles of six
travellers who acquired Zika virus infection in Southeast
Asia, French Polynesia, and Latin America.49 Significant
elevation of multiple cytokines (including interleukins 1b,
2, 4, 6, 9, 10, 13, 17, and IP-10) was observed during acute
infection, but not interferon-gamma or tumour necrosis
factor-alpha, suggesting a cytokine response towards Th2
reaction. Interleukins 1b, 6, 8, 10, 13, IP-10, RANTES, MIP-
1a, MIP-1b, VEGF, FGF, and GM-CSF were elevated during
the convalescent phase. The “cytokine storm” which occurs
in some other viral infections was not demonstrated in the
small cohort of subjects.Epidemiology and transmission
Since its initial discovery, early virological and serological
studies from the 1950s to 1980s showed that Zika virus
infection is predominantly limited to African and Asian
countries.50 In Asia, endemic circulation of the virus (clin-
ical disease and/or seroprevalence studies) has been re-
ported in Indonesia, Cambodia, Thailand, The Philippines,
Peninsular Malaysia, and Borneo, and among travellersreturning from endemic areas.51e58 The first major
epidemic outside Africa occurred in Yap Island of the
Federated States of Micronesia (in the western Pacific
Ocean, north to Papua New Guinea) in 2007 (Table 3). Since
then, Zika, dengue, and chikungunya viruses became
rampant in the Pacific islands.61 Another major epidemic
occurred in the western Pacific islands of French Polynesia
and New Caledonia in 2013e2014.64
The outbreak in Easter Island in 2014 heralded the
incursion of the virus to mainland Latin America.62 Since
early 2015, Brazil reported the first autochthonous case in
the city of Natal and this was quickly followed by another
large epidemic in Brazil and neighbouring countries in Latin
America.63,65e68 As of 12 February 2016, there were over
2,000 confirmed and over 118,000 suspected cases in the
Americas.69 The exact time and route of spread of the virus
to Brazil is unknown, but importation during the 2014 World
Cup has been postulated.65
The virus is epizootic and enzootic in non-human pri-
mates in Africa (sylvatic cycle), and these mammals are the
most important natural reservoir hosts.70 However, as in
the case of other arboviruses such as dengue and yellow
fever, urban cycles involving humandmosquitodhuman
transmission can readily occur when there are competent
anthropophilic vectors. Aedes mosquitoes are the primary
vectors for natural transmission of the Zika virus. The
extrinsic incubation period of the virus in mosquitoes is
about 10 days (similar to the 8e12 days required of dengue
virus).50,71 In Ae. aegypti, high levels of viruses could be
found within the mosquitoes from days 20e60 after infec-
tion, though the average lifespan of female Ae. aegypti
adults is shorter than this in the tropical field condi-
tions.71,72 Species from which the virus has been isolated or
found to be capable of transmitting the virus include Ae.
africanus (chiefly a forest-dwelling mosquito feeding on
non-human primates), Ae. apicoargenteus (an African
mosquito species), Ae. luteocephalus (an African mosquito
species), Ae. furcifer (an African mosquito species), Ae.
232 S.S.-Y. Wong et al.vittatus (worldwide distribution), Ae. unilineatus (found in
Africa and parts of Asia, including India, Pakistan, and Saudi
Arabia), Ae. opok (an African mosquito species described in
Uganda), Ae. hensilli (endemic species in Micronesia,
implicated in the outbreaks of dengue, chikungunya, and
Zika virus infections in Yap Island of Micronesia), Ae.
aegypti, and Ae. albopictus.59,60,73e79 To most countries of
the world, the last two species, Ae. aegypti and Ae. albo-
pictus (nowadays more properly known as Stegomyia
aegypti and Stegomyia albopicta respectively),80 may pose
the greatest threats, given their almost ubiquitous pres-
ence in many tropical and subtropical countries, their
adaptation to the urban and peri-domestic environments,
their highly anthropophilic behaviours, invasion into some
European and North American countries, and competence
to act as vectors for numerous other arboviruses.81 Ae.
aegypti, in particular, is considered to be the prime vector
for the transmission of Zika virus among humans. Ae.
aegypti and Ae. polynesiensis are suspected to be the
vectors involved in the French Polynesian outbreak.82,83 In
additon, Zika virus has also been isolated from other non-
Aedes genera of mosquitoes including Mansonia uniformis,
Culex perfuscus, and Anopheles coustani.84 However, it
must be remembered that the ability to isolate the virus
from certain mosquito species and their in vitro compe-
tence to support viral replication does not mean that those
species are necessarily important vectors epidemiologi-
cally. As in the case of other vectorborne infections, the
vectorial capacity depends not only on vector competence,
but also on the local density of the vectors, their host biting
preference, feeding frequency, longevity (which is relevant
to the extrinsic incubation period of the arbovirus), and
level of viral replication in the vectors.85e87
In addition to mosquitoes, other routes of transmission
of Zika virus are possible, although these are unlikely to be
of major epidemiological significance under natural cir-
cumstances. Direct transmission from primates to human
via animal bites has been suggested though not proven.88
Coincidentally, Zika virus has also been detected in the
saliva of 19.2% of infected individuals but the epidemio-
logical significance of this remains to be determined.89
Sexual transmission has been documented, and the virus
has been detected in the semen up to 62 days after onset of
febrile illness.90e92 Likewise, perinatal and congenital in-
fections can occur.42,93 Another major clinical and public
health concern is the potential for transmission through
transfusion and transplantation. In endemic countries, the
proportion of asymptomatic or subclincial flaviviral in-
fections far exceeds the clinically overt cases. For
example, the ratios between asymptomatic or inapparent
to clinical cases of dengue, Japanese encephalitis, and
yellow fever are 3e18:1, 250:1, and 7e12:1
respectively.94e96 Detection of arboviruses in donated
blood and their transmission through transfusion have been
well documented for arboviruses such as dengue, West Nile,
and tick-borne encephalitis viruses, with concerns over
other viruses such as chikungunya and Ross River
viruses.97e103 During the French Polynesian Zika outbreak in
2013e2014, 3% of asymptomatic blood donors were found
to be viraemic using RT-PCR screening, thereby under-
scoring the potential for transfusion transmission of Zika
virus.104Clinical and laboratory aspects
Clinically, Zika virus infection cannont be reliably differ-
entiated from other arbovirus infections such as dengue
and chikungunya as the symptoms and signs are not
pathognomonic. The clinical and epidemiological features
are also confounded by co-circulation of different arbovi-
ruses in the same geographical area.60 Table 4 compares
some of the features of dengue, Zika, and chikungunya.
After an incubation period of 3 to 12 days, Zika virus
infection presents initially with headache, a descending
maculopapular rash involving palms and soles (which can be
pruritic), fever, malaise, myalgia, anorexia, conjunctivitis,
arthralgia, limb oedema and sometimes abdominal symp-
toms (abdominal pain, diarrhoea).50,105 Limb oedema and
conjunctivitis appeared to be commoner with Zika virus
infections than dengue or chikungunya, while hepatomeg-
aly, leukopenia, and thrombocytopenia were less common
in Zika virus infections.105 During the Yap outbreak, the
main clinical manifestation (incidence in parentheses) were
maculopapular rash (90%), fever (65%), arthritis/arthralgia
(65%), conjunctivitis (55%), myalgia (48%), headache (45%),
retro-orbital pain (39%), oedema (19%), and vomiting
(10%).59 Serious complications due to Zika virus infection
were rarely reported in the past. However, during the
French Polynesian outbreak, an increased incidence of
Guillain-Barre´ syndrome was noted, with an incidence that
is 20 times higher during the outbreak than non-outbreak
periods.83,115 An association with Guillain-Barre´ syndrome
was also noted in the Latin American epidemic since 2015.
In Brazil, 62% of the Guillain-Barre´ syndrome patients dur-
ing the outbreak had preceding symptoms consistent with
Zika virus infection.63 Death from Zika virus infection in
adults is rare but has been reported, although the exact
contribution of the infection to mortality has not been
detailed at the moment.116 The duration of immunity after
recovery from Zika virus infection is unknown. Co-infection
with other arboviruses is possible, since the key Aedes
vectors are capable of transmitting other arboviruses.117
The most striking and unexpected sequel of Zika virus
infection is the possible association with congenital ab-
normalities, in particular, microcephaly. In some cases,
intrauterine or neonatal death may ensue.116 The epide-
miological linkage was first observed in Brazil in 2015,
where the number of infants born with microcephaly
increased 20 times after the onset of the epidemic, with
over 1200 cases being reported in 2015 (99$7 per 100,000
livebirths).118 As of 30 January 2016, there were 4,783 cases
of congenital central nervous system malformations recor-
ded in Brazil (compared to an annual incidence of 163
microcephaly cases in 2001e2014) with 76 deaths.63 In
addition to microcephaly, affected foetuses and infants
also have cerebral calcification seen in imaging.119,120 In
microcephalic infants, retinal abnormalities manifesting as
macular neuroretinal atrophy, macular pigment mottling,
foveal reflex loss, and chorioretinal atrophy, as well as
optic nerve hypoplasia were also observed.118,120 Ophthal-
mological examination of the infected mothers was uni-
formly normal.
The management of pregnant women with Zika virus
infection remains problematic. The main difficulties
Table 4 Epidemiological and clinical features of dengue, Zika, and chikungunya virus infections.59,61,105e114
Dengue virus Zika virus Chikungunya virus
Virology
Family Flaviviridae Flaviviridae Togaviridae
Nucleic acid Single-strand, positive sense,
RNA.
Single-strand, positive
sense, RNA.
Single-strand, positive sense, RNA.
Main divisions 4 serotypes (1 to 4) 2 lineages (African
and Asian)
4 major lineages (West African,
East/Central/South African [ECSA],
Indian Ocean, Asian)
Epidemiology
Natural
reservoir
Primates (sylvatic cycle). Primates (sylvatic cycle). Primates (sylvatic cycle).
Key vectors
for natural
transmission
Aedes mosquitoes.
Sylvatic cycle: Ae. furcifer, Ae.
luteocephalus, Ae. vittatus,
Ae. taylori, Ae. niveus.
Urban cycle: Ae. aegypti and
Ae. albopictus, other locally
predominant species implicated
(e.g. Ae. polynesiensis,
Ae. pseudoscutellaris,
Ae. malayensis, Ae. cooki).
Aedes mosquitoes.
Sylvatic cycle: Ae. africanus,
Ae. furcifer, Ae. luteocephalus,
Ae. vittatus, Ae. unilineatus,
Ae. opok.
Urban cycle: Ae. aegypti,
Ae. albopictus; other locally
predominant species implicated
(e.g. Ae. hensilli, Ae.
polynesiensis).
Aedes mosquitoes.
Sylvatic cycle: Ae. africanus, Ae.
furcifer, Ae. luteocephalus, Ae.
neoafricanus, Ae. taylori, Ae.
dalzieli, Ae. vigilax, Ae.
camptorhynchites, Ae. fulgens.
Possibly Mansonia spp. as well.
Urban cycle: Ae. aegypti, Ae.
albopictus.
Endemic areas Tropics and subtropic areas.
Widespread in Asia, Africa,
Latin America, Pacific islands,
northeast Australia. Increasing
cases reported in southwestern
and southeastern United States.a
Asia: Cambodia, Indonesia,
Malaysia, Pakistan, The
Philippines, Thailand.
Pacific islands: Micronesia,
French Polynesia, New
Caledonia, The Cook Islands.
Africa: Senegal, Uganda,
Nigeria, Coˆte d’Ivoire, Gabon,
Tanzania, Egypt, Central
African Republic, Sierra Leone.
Latin America: since 2015.b
Widespread in sub-Saharan Africa,
Asia, Latin America, Pacific islands,
Indian Ocean islands.c
Europe: local transmission in
northern Italy (2007) and southern
France (2014) following
importation of the virus.
Iatrogenic
transmission
Transfusion-transsmission
confirmed; possibly
renal transplantation.
One case of transfusion-
transmitted infection declared
by Brazilian authorities.d
Transfusion-transmission
potentially possible.
Vertical
infections
Yes. No congenital
abnormalities reported.
Yes. Possible association with
microcephaly and maculopathy.
Yes. Possible centro-facial
hyperpigmentation.
Sexual
transmission
Not reported. Yes. Not reported.
Clinical features
Incubation
period
3e10 days (usually 5e7 days). 2e12 days (usually 2e7 days). 2e6 days.
Duration of
viraemia
2e3 days before to 4e5
days (range: 2e12 days)
after onset of symptoms.
Usually 3e5 days after onset
of symptoms (possibly over
11 days in some cases). Duration
of viraemia prior to disease
onset unknown.
About 6 days after onset of
symptoms (range: 3e10) days.
Asymptomatic
infection
14% in adults, 53% in children.
Over 75% in
some series.
80%. 3e37%.
Common clinical
manifestations
Fever, headache, retro-orbital
pain, maculopapular rash or
“white islands in a sea of red”,
arthralgia, myalgia.
Fever, headache, conjunctivitis,
itchy maculopapular rash,
arthralgia (small joints of hands
and feet), oedema of
extremities, oral ulcers.
Fever, rash, myalgia, polyarthralgia,
polyarthritis, diarrhoea, vomiting,
abdominal pain.
(continued on next page)
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Dengue virus Zika virus Chikungunya virus
Uncommon
or severe
manifestations
Severe dengue: vascular leakage,
haemoconcentration, bleeding
diathesis, shock, end organ
involvement (previously
referred to as dengue
haemorrhagic fever and
dengue shock syndrome)
Guillain-Barre´ syndrome,
encephalitis, meningoencephalitis.
Possible congenital infection
leading to microcephaly and
maculopathy.
Conjunctivitis, uveitis, iridocyclitis,
retinitis, meningoencephalitis,
myocarditis, hepatitis, multi-organ
failure.
Case-fatality
ratio
Less than 1% to 5% with dengue
fever. Severe dengue without
adequate treatment, up to 20%
or above, but can be reduced to
less than 1% with proper
management.
Very low. 0.1%.
Key laboratory
findings
Leukopenia, lymphopenia,
thrombocytopenia,
elevated transaminases.
Haemoconcentration
(increased haematocrit) and
coagulation abnormalities in
severe dengue.
Relatively normal blood tests.
Occasional mild thrombocytopenia,
leukopenia with monocytosis
reported.
Leukopenia, lymphopenia,
thrombocytopenia, hypocalcaemia,
elevated transaminases.
Diagnostic tests
of choice
NS1 antigen detection, RT-PCR,
antibody detection.
RT-PCR, antibody detection
(ELISA and neutralization assay).
RT-PCR, antibody detection.
Antiviral
therapy
None. None. None.
Vaccine
prevention
Vaccine first marketed in 2015. None. None.
a Updated map of countries with dengue transmission can be found at http://www.healthmap.org/dengue/en/.
b Updated map of American countries with autochthonous Zika virus transmission during the 2015 outbreak can be found at Regional
Office for the Americas of the World Health Organization, http://www.paho.org/hq/index.php?optionZcom_content&viewZ
article&idZ11669&ItemidZ41716&langZen.
c Updated map of countries with chikungunya transmission can be found at http://www.cdc.gov/chikungunya/geo/.
d Quoted by the Center for Infectious Disease Research and Policy, The University of Minnesota, on 4 February 2016. No official sci-
entific publications are available at the time of writing. Available at: http://www.cidrap.umn.edu/news-perspective/2016/02/brazil-
confirms-blood-transfusion-zika-paho-calls-global-support. [accessed 18.02.16.].
234 S.S.-Y. Wong et al.include the uncertainty of the risk of developing congenital
abnormalities after infection of the pregnant women, the
risk associated with infection at different time of gestation,
and the lack of alternative antenatal diagnostics other than
imaging studies. Current guidelines generally recommend
monitoring of pregnant women with a recent travel history
to endemic areas, early diagnosis of infection, close ante-
natal and postnatal surveillance and monitoring of infected
women, exclusion of other congenital infections (such as
toxoplasmosis, cytomegalovirus infection, rubella), amnio-
centesis for virological investigations if radiological abnor-
malities are detected, and consideration of termination of
pregnancy after thorough counselling of the pregnant
women.116,121,122 Zika virus can be detected by RT-PCR in
the amniotic fluid of microcephalic foetuses, but the posi-
tive and negative predictive values of the RT-PCR finding
(either in the amniotic fluid or even chorionic villus sam-
pling) for the development of congenital abnormalities are
unknown, and the test has not been well evaluated for
specimens other than blood.93,116,122
Zika virus can be cultured in a number cell lines such as
Vero and LLC-MK2, or by intracerebral inoculation ofsuckling mice.123 While these are useful for virological
studies and research, they are impractical for most clinical
laboratories. Laboratory-acquired infections of Zika virus
have also been reported.50 Zika virus is classified as a
biosafety level 2 organism according to the US CDC and
human pathogen hazard group 3 according to the UK Advi-
sory Committee on Dangerous Pathogens.124,125 Antibody
detection and nucleic acid amplification using RT-PCR are
the usual diagnostic tests of choice. A commercial system
(EUROIMMUN AG, Lu¨beck, Germany) detecting anti-Zika IgG
and IgM using ELISA (with recombinant NS1 antigen) and
indirect immunofluorescence assay (which also allows dif-
ferentiation between Zika, chikungunya, and dengue vi-
ruses) was marketed in January 2016. An in-house ELISA
antibody test was developed during the Yap outbreak by
the Centers for Disease Control and Prevention, USA. As
expected, IgG and IgM antibody testing using ELISA shows
cross-reaction with other flaviviruses, especially in patients
with prior flaviviral infections. IgM antibodies are detect-
able from days 3e8 after onset of illness. Antibody testing
by the plaque reduction neutralization test is more spe-
cific.44 In-house indirect immunofluorescent assays have
Zika virus infection 235also been described for antibody detection.126 Although
antibody testing suffers from cross reactivities with other
flaviviruses, it remains an essential diagnostic means,
especially in patients who presented late in the course of
disease where RT-PCR tests could be negative (about
5e7 days after onset of disease).126 The usual laboratory
test of choice for acute Zika virus infections is RT-PCR on
clinical samples, most commonly the peripheral blood. RT-
PCR allows accurate differentiation of Zika virus from other
pathogens which may share similar clinical manifestations,
and this is especially useful in areas where co-circulaion of
different arboviruses is prevalent. Genotyping of the viral
strains is also possible. In the Yap outbreak, one third of the
sera collected within 10 days after disease onset were still
positive by RT-PCR.59 PCR protocols have been developed
using primers directed towards various targets including E,
NS5, and prM/E, and M.44,51,127e129 Duration of viraemia in
humans ranges from 1 to more than 11 days after the onset
of disease.50 The viral load in patient sera appears to be
relatively low, ranging from 930 to 728,800 (median:
21,495) copies/mL in a series of 17 patients in the Yap
outbreak in 2007 (sera were mostly collected within 3 days
after onset of disease).44 One patient in that study had a
viral load of 338,797 copies/mL when the blood was
collected on day 11 after disease onset. Zika virus RNA has
also been detected in the saliva, urine, and semen of some
patients; remarkably, the positive rate of RT-PCR in saliva is
higher than that of blood (57.1% vs. 28.1%).89,91,130 The
additional value of performing RT-PCR on urine and saliva
over blood, other than the ease of specimen collection, is
unknown because the viral kinetics in these body fluids
have not been determined.
The NS1 antigen of dengue virus has revolutionized the
laboratory diagnosis of dengue, providing a simple and
rapid point-of-care diagnostic means with high specificity
and ability to diagnose the infection early in the course
(especially in the first 3 days after disease onset).131
Although commercially available NS1-based diagnostic
technique is currently limited to dengue, this may poten-
tially be applicable to other flaviviral infections because
circulating NS1 antigens have also been detected in Japa-
nese encephalitis and West Nile virus infections.132,133 No
information on the detection of circulating NS1 antigen in
Zika virus infection is currently available. Caution should be
excercised in the interpretation of dengue NS1 antigen
testing results, for false positive result has been reported in
a patient with acute Zika virus infection and other under-
lying diseases.134,135
Treatment of Zika virus infection is primarily supportive.
Nonsteroidal anti-inflammatory drugs should be avoided
unless dengue has been excluded.116,122 Standard pre-
cautions in health care settings are adequate, with addi-
tional measures in mosquito-proofing of the health care
facilities. Insect repellents and mosquito bite avoidance
are recommended for health care workers looking after
Zika patients.116 It would be prudent to recommend pa-
tients in the first one to two weeks after the onset of illness
to adhere to bite avoidance measures in order to reduce
the risk of secondary transmission. No antivirals are
currently licensed for specific therapy against flaviviral in-
fections (except hepatitis C virus), although in vitro studies
with therapeutic antibodies, small interfering RNA, andmolecules against non-structural proteins (especially NS3
and NS5 proteins) are ongoing.136e138 A few currently
available drugs such as the tetracyclines, chloroquine,
amodiaquine, and mefenamic acid have shown in vitro
inhibitory acitivities against flavivirus (mostly with dengue
virus), but it is still too early to comment on their potential
clinical benefits.139e144Prevention
Pregnant women are discouraged from travelling to Zika-
endemic areas.145 In addition to bite avoidance measures,
non-pregnant, sexually active women of reproductive age
residing in endemic areas should consider the issues of
family planning and contraception, taking into account
various social and religious precepts.122 At present, the only
flaviviral vaccines available for human use are yellow fever
(live attenuated), Japanese encephalitis (inactivated, live
attenuated, and chimeric), tick-borne encephalitis (inac-
tivated) vaccines, and the newly marketed dengue vaccine
(live attenuated, recombinant, tetravalent; marketed since
2015). Claims were made by an Indian biotechnology com-
pany that two Zika virus vaccine candidates (recombinant
and inactivated) can be tested soon; however, no details on
the vaccine preparations are currently available in the
scientific literature.146 In any case, a normal vaccine
development cycle usually requires years of preclinical and
clinical studies and a Zika virus vaccine for human use is
unlikely to be available in the near future.
In the absence of vaccines or chemoprophylaxis, the
prevention of Zika virus infection follows the general rules
for other vectorborne infections. Broadly speaking, this
involves two major areas, personal protection through bite
avoidance and vector control. Bite avoidance is equally
important to both residents in and travellers to endemic
areas. Personal protection includes general measures such
as protective clothings, proper choice and use of insect
repellents, and mosquito-proofing of houses. The use of
insecticide-impregnated bednets has been one of the core
elements in the prevention and control vectorborne dis-
eases such as malaria in endemic countries. However, its
role against the Aedes vectors of Zika virus depends on the
behaviours of the vectors in specific geographical areas. In
general, Ae. aegypti mosquitoes are endophilic (resting
indoors), endophagous (biting indoors), anthropophagic
(preferentially biting humans), and diurnal and crepuscular
in their activities. Ae. albopictus mosquitoes are generally
exophilic (resting outdoors), exophagous (biting indoors),
and anthropophilic, and are aggressive daytime
biters.147e149 However, it is known that the endophilic/
exophilic and endophagous/exophagous behaviours are not
absolute and these can be variable in different geograph-
ical areas.150 A thorough knowledge of the local mosquitoes
and their behaviours are therefore crucial to the control of
vectorborne diseases, and this underlines the importance
of long-term local vector surveillance.
The proper use of insect repellents is the keystone in
personal protection against haematophagous arthropods. A
number of insect repellents are widely available on the
market, each of which has different repellent efficacies
against different mosquito genera and other arthropods
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against it in recent years, N,N-diethyl-m-toluamide (DEET)
remains the gold standard in insect repellents against which
other newer compounds are benchmarked. DEET was
initially developed and patented by the US Army in 1946
and commercialized since 1957. It is generally applied to
skin in the form of liquids, aerosols, or lotions, and can be
used to impregnate clothings if necessary (although
permethrin is more commonly used for this purpose).
Commercially available DEET formulations range from 4% to
100% in concentration. It is a common misconception that
higher concentrations provide “more powerful” protection
against arthropods. Higher concentrations merely prolong
the duration of protection. At a concentration of 15%, DEET
protects against Ae. aegypti and Ae. albopictus bites for
about 7e8 hours.151 The effect plateaus at a concentration
of about 50%. Although percutaneous absorption of DEET
does occur, the level is extremely low as compared to the
lethal doses observed in animals.152,153 DEET has an excel-
lent record of safety and efficacy after 60 years of use. It is
not oncogenic, teratogenic, or genotoxic at maximum
tolerated doses in animals. Reports of serious human
toxicity mainly relate to neurotoxicity, especially seizures
in children. However, such reports remained rare (when
compared to the total number of individuals exposed to
DEET over the years) and in many of the reported cases, a
definitive causal relationship between DEET and neurotox-
icity cannot be established (other than the few cases of
deliberate or accidental ingestion in huge quantities or
improper use of the products).154e158 Similarly, although
detectable levels of DEET can be found in cord blood of
infants born to mothers using DEET during second and third
trimesters of pregnancy, no adverse outcomes of pregnancy
have been found in a double-blind, randomized trial.159
Hence, when used appropriately according to recommen-
dations, DEET is still considered to be safe in children older
than 2e6 months of age, as well as in pregnant and
lactating women.160e164 A DEET concentration of 20% to 30%
is generally recommended for adult use.
Effective and safe alternatives to DEET are available.
The most commonly used ones are ethyl butylacetylami-
nopropionate (IR3535, more effective against Aedes and
Culex than Anopheles mosquitoes), picaridin (also known as
icaridin; concentrations of 20% are needed), p-menthane-
3,8-diol (PMD), and possibly 2-undecanone
(BioUD).151,165,166 For impregnation of clothings, shoes,
and other equipment, permethrin is generally preferred.158
Various botanical compounds have been advocated as nat-
ural and harmless insect repellents. These are often
essential oils extracted from plants. While many of these
oils do possess repellent activities, most of them are too
volatile to offer lasting protections (usually lasting for less
than 1 hour) and even these natural products may cause
adverse reactions, especially skin irritation.158,165,167e169
Insect repellent-treated wristbands, garlic, oral vitamin B,
and electronic buzzers (which claim to produce ultrasound
to repel insects) are completely ineffective as bite avoid-
ance measures.165,169 Whichever insect repellent is chosen,
one must beware of potential limitations, such as repeating
the application after heavy sweating, swimming, or raining,
and applying the repellent about 20 minutes after the
application of sunscreens. For international travellers,preventive measures against other vectorborne infections
should not be forgotten. These include the use of antima-
larial chemoprophylaxis and yellow fever vaccination (as
dictated by the destination) as appropriate, as there are
overlaps in the current endemic areas of these infections
and the possibility of further spread of Zika virus infection
in the future.170 Vaccination against Japanese encephalitis
and tick-borne encephalitis may be considered for travel-
lers to endemic areas with high-risk exposures, and dengue
vaccination may potentially be considered in the future
when more data are available.
Vector control is the only long-term solution to the
control of vectorborne diseases. During outbreak situations,
emergency measures such as the use of space spray
(fogging) may be deployed to rapidly bring down the num-
ber of biting adults and terminate disease transmission.
However, this is not a sustainable measure in the long run.
The details of mosquito control are beyond the scope of this
article. In brief, this mainly involves source reduction by
larval control. Ae. aegypti and Ae. albopictus are typical
container-breeding species which thrive in urban and man-
made environments. Unlike other mosquites which breed in
open water areas, environmental management measures
are less likely to be effective. Raising the awareness of the
community and engaging citizens in source reduction in
households and their vicinity is the key to success in con-
trolling these mosquito species.171,172 Other means of
mosquito control, some of which are still experimental or in
the early phases of field trials, include the use of biological
measures such as entomopathogenic fungi and genetic
measures including sterile insect techniques.172,173 Obvi-
ously, all vector control strategies have to be continued as
perennial exercises because various mosquito genera,
including Aedes spp., are capable of overwintering, and
that the eggs of Aedes mosquitoes are well known for their
ability to withstand prolonged periods of desic-
cation.174e176 Vector control measures must go hand in
hand with vector surveillance, not only to monitor the
density of mosquitoes (which may sometimes be correlated
with the risk of transmission), but also to detect coloniza-
tion by invasive species which may contribute to local
spread of the infection.177e179 The public health signifi-
cance of vector control and surveillance cannot be over-
stated. Aedes mosquitoes, in particular, Ae. aegypti and
Ae. albopictus, are notorious for their vectorial capacity in
transmitting multiple vectorborne infections. Dengue, for
example, has taken its toll in many continents. From 4
January 2015 to 14 February 2016, 44,196 cases of dengue
fever have been recorded in Taiwan, making it one of the
biggest outbreaks of the disease on the island.180 Given the
fact that the competent vectors Ae. aegypti and Ae.
albopictus are highly prevalent in many tropical and sub-
tropical countries, the potential for Zika virus to cause
outbreaks, and worse, co-circulation with other arbovi-
ruses, in these areas is very high.181
The role of border screening in preventing the impor-
tation of infectious diseases has previously been dis-
cussed.182 Although this is deployed in many countries
(especially among Asian countries), border screening
cannot reliably detect all infected individuals because of
the asymptomatic incubation period. In the prevention of
Zika virus infection, perhaps a more realistic approach is to
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may involve travel medicine specialists in travel clinics as
part of the pre-travel consultation, as well as reinforcing
publicity and education in airports and other departure
points. Of particular importance is a thorough pre-travel
counselling of pregnant women intending to go to
endemic areas for various arthropod-borne infections. This
group of travellers may pose special difficulties in terms of
vaccination, chemoprophylaxis, and choice of personal
protection.183 Exclusion of individuals with a recent history
of travel to endemic areas from blood and organ donation
would be a prudent precautionary measure. Given the risk
of sexual transmission of Zika virus, abstinence or barrier
contraceptives should be used by persons with recent visits
to endemic areas and patients recovered from the illness.
Nevertheless, because the longest duration of viraemia and
viral shedding in other body fluids (such as semen, urine,
and saliva) is presently unknown, the duration required for
these precautions are at best tentative. For asymptomatic
returned travellers, some authorities recommended that
barrier contraception should be used for 28 days after
returning, and for 6 months after recovery if
symptomatic.121,184Conclusion
The geographical distribution of Zika virus has expanded
tremendously since 2007. The threat of further expansion is
real because of the constant increase in the volume of in-
ternational travel, difficulties in controlling Aedes pop-
ulations, invasion of Aedes species to more temperate
countries, and global climate change which may increase
the geographical extents favourable to the breeding of
mosquitoes. Nucleic acid amplification remains the main
diagnostic test of choice, though the availability of com-
mercial antibody detection assays should complement
laboratory diagnosis of the infection. Control measures
currently relies on standard bite avoidance measures by
residents and travellers alike, as well as integrated vector
management in the community. The unique challenge of
Zika virus infection lies not only on disease control, but the
potential sequelae of congenital infection and severe
neurological complications. Further studies may provide
insights to the pathogenic mechanisms, earlier and more
sensitive predictors of congenital abnormalities, and the
possibilities of vaccination.References
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